Evidence map›Paper›PMID 33923897›Full record

ArticlePharmaceutics2021

Polymeric Caffeic Acid Acts as a Nasal Vaccine Formulation against

Rui Tada, Hidehiko Suzuki, Miki Ogasawara, Daisuke Yamanaka, Yoshiyuki Adachi, Jun Kunisawa, Yoichi Negishi

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Mucosal immunotherapy targeting APC in lung disease.Journal of inflammation (London, England) · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Polymer-Based Nanosystems-A Versatile Delivery Approach.Materials (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rui TadaDepartment of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.ORCID 0000-0003-0098-9587
Hidehiko SuzukiLaboratory of Vaccine Materials and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
Miki OgasawaraDepartment of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
Daisuke YamanakaLaboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.ORCID 0000-0002-0046-7052
Yoshiyuki AdachiLaboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.ORCID 0000-0001-7164-6237
Jun KunisawaLaboratory of Vaccine Materials and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
Yoichi NegishiDepartment of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
Tokyo University of Pharmacy and Life Sciences · JPNational Institute of Biomedical Innovation, Health and Nutrition · JP

Funding

Japan Agency for Medical Research and Development 20ak0101068h0004Japan Agency for Medical Research and Development 20fk0108145h0001Japan Society for the Promotion of Science (JSPS) 18H02150Japan Society for the Promotion of Science (JSPS) 18H02674Japan Society for the Promotion of Science (JSPS) 18K06798
6 · The paper itself

Abstract

Infectious diseases are the second leading cause of death worldwide, highlighting the importance of the development of a novel and improved strategy for fighting pathogenic microbes.

Indexed as

mucosal adjuvantmucosal vaccinepolyphenolPspAStreptococcus pneumoniae

Identifiers

PMID33923897
PMCPMC8073337
OpenAlexW3153697861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.